This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Giotrif
  • /
  • LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992...
Clinical trial

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Read time: 1 mins
Last updated:1st Dec 2011

This is a randomised, open-label, phase IIb trial of afatinib to compare to gefitinib in first-line treatment setting with patients who are having epidermal growth factor receptor mutation positive advanced adenocarcinoma of the lung.

Study Type: Interventional
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomised, Open-label Phase IIb Trial of Afatinib Versus Gefitinib as First-line Treatment of Patients With EGFR Mutation Positive Advanced Adenocarcinoma of the Lung
Enrollment: 319
Study Start Date: December 2011
Estimated Study Completion Date: December 2016
Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)

- Experimental:
- Active Comparator: gefitinib

Category Value
Study start date 2011-12-01

View full details